Gilead Sciences, Inc. posted strong revenue growth for the fourth quarter and full year 2022, reporting rapidly growing sales, especially for its top-selling cancer cell therapy and its HIV products, even as sales of its COVID-19 drug, Veklury (remdesivir), continued to see steep declines that appeared to track an overall weakening for the pandemic category across the industry.
The Foster City, CA-based drug maker announced its earnings for 2022 on 2 February, reporting total sales for the fourth...








